Influence of Anti-Hyperlipidemic Agents on Renal Functions of Patients Having Normal Kidney.

Acute coronary syndrome (ACS) was recently revealed to occur when a fragile plaque in a fibrous capsule breaks off and a thrombus produced at the broken site obstructs the vascular cavity. Anti-hyperlipidemic agents have been reported to be effective in preventing this onset of ACS through its stabilizing effect on these plaques, thereby leading to its extensive application. However, no reports have yet comparatively examined the influence of two combined antihyperlipidemic agents of different species on the renal functions including blood urea nitrogen (BUN) and serum creatinine (Scr) in patients whose kidneys function normally. Therefore, BUN, total cholesterol (TC), neutral triglyceride (TG), high density lipoprotein (HDL), and low density lipoprotein (LDL) were comparatively analyzed before and one year after treatment with single pravastatin (CS), single bezafibrate (BF) or CS-F BF combination in patients first diagnosed to have hyperlipidemia at our hospital. While TC and LDL significantly decreased in the CS group, TG significantly decreased and HDL significantly increased in the BF group. In the CS-FBF combination group, TC, TG and LDL significantly decreased while HDL significantly increased. In the three groups, no significant increase was detected for BUN or Scr. As mentioned above, the administration of CS and BF to patients with normal renal functions therefore appears to be safe since no renal disturbances were observed.